Literature DB >> 32721432

Berberine attenuates severity of chronic pancreatitis and fibrosis via AMPK-mediated inhibition of TGF-β1/Smad signaling and M2 polarization.

Sapana Bansod1, Nandkumar Doijad1, Chandraiah Godugu2.   

Abstract

Berberine (BR) acts as an AMP-activated protein kinase (AMPK) activator which possesses antioxidant and anti-inflammatory properties. In this study, we have investigated the effects of BR against cerulein-induced chronic pancreatitis (CP) via inhibition of TGF-β/Smad signaling and M2 macrophages polarization in AMPK dependent manner. Cerulein-induced CP mice were treated with BR (3 and 10 mg/kg), intraperitoneally every day for 21 days. Our results indicated that, BR treatment (10 mg/kg) significantly reduced oxidative-nitrosative stress, histological alterations, inflammatory cells infiltration and collagen deposition in pancreatic tissue. BR treatment also prevented cerulein-induced pancreatic stellate cells (PSCs) activation and extracellular matrix (ECM) deposition via downregulation of α-SMA, collagen1a, collagen3a and fibronectin expression. Mechanistically, treatment with BR significantly activated AMPK signaling as compared to cerulein-challenged mice. Further, administration of BR also inhibited TGF-β/Smad signaling and macrophages polarization in cerulein-induced CP in-vivo models and TGF-β1 stimulated RAW 264.7 macrophages in-vitro. Together, our results strongly suggest that BR treatment protected against cerulein-induced CP and associated fibrosis progression by inhibiting TGF-β1/Smad signaling and M2 macrophages polarization in an AMPK dependent manner.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AMP-activated protein kinase; Berberine; Chronic pancreatitis; M2 macrophages polarization; TGF-β1/Smad

Year:  2020        PMID: 32721432     DOI: 10.1016/j.taap.2020.115162

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  7 in total

1.  Berberine Suppressed the Progression of Human Glioma Cells by Inhibiting the TGF-β1/SMAD2/3 Signaling Pathway.

Authors:  Yun Jin; Jiawei Zhang; Yunfeng Pan; Wangzhen Shen
Journal:  Integr Cancer Ther       Date:  2022 Jan-Dec       Impact factor: 3.077

2.  Layered Double Hydroxides-Loaded Sorafenib Inhibit Hepatic Stellate Cells Proliferation and Activation In Vitro and Reduce Fibrosis In Vivo.

Authors:  Wei Peng; Shiwen Zhang; Wei Zhou; Xinchen Zhao; Kexue Wang; Chengxu Yue; Xinyu Wei; Siyan Pang; Wei Dong; Sulian Chen; Changjie Chen; Qingling Yang; Wenrui Wang
Journal:  Front Bioeng Biotechnol       Date:  2022-05-27

3.  Translational research in anti-pancreatic fibrosis drug discovery and development.

Authors:  Xingyu Ze; Wenbin Zou; Zhaoshen Li
Journal:  J Transl Int Med       Date:  2021-12-31

4.  Murine Chronic Pancreatitis Model Induced by Partial Ligation of the Pancreatic Duct Encapsulates the Profile of Macrophage in Human Chronic Pancreatitis.

Authors:  Cheng Peng; Guangping Tu; Li Yu; Peng Wu; Xianlin Zhang; Zheng Li; Zhiqiang Li; Xiao Yu
Journal:  Front Immunol       Date:  2022-04-01       Impact factor: 8.786

5.  Inhibition of discoidin domain receptors by imatinib prevented pancreatic fibrosis demonstrated in experimental chronic pancreatitis model.

Authors:  Sapana Bansod; Mohd Aslam Saifi; Chandraiah Godugu
Journal:  Sci Rep       Date:  2021-06-18       Impact factor: 4.379

6.  Protective Effect of Jiang Tang Xiao Ke Granules against Skeletal Muscle IR via Activation of the AMPK/SIRT1/PGC-1α Signaling Pathway.

Authors:  Ying Bai; Jiacheng Zuo; Xin Fang; Rufeng Ma; Tian Tian; Fangfang Mo; Qianqian Mu; Yi Zhang; Na Yu; Xueli Bao; Dongwei Zhang; Sihua Gao; Dandan Zhao
Journal:  Oxid Med Cell Longev       Date:  2021-07-03       Impact factor: 6.543

7.  Human umbilical cord-derived mesenchymal stem cells improve chronic pancreatitis in rats via the AKT-mTOR-S6K1 signaling pathway.

Authors:  Lijun Kong; Xiangxiang Xu; Hewei Zhang; Yi Zhou; Hongjian Huang; Bicheng Chen; Zhenxu Zhou
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.